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F I B R O S I S
Plasmacytoid dendritic cells promote systemic sclerosis 
with a key role for TLR8
Marie Dominique Ah Kioon,1 Claudio Tripodo,2 David Fernandez,3 Kyriakos A. Kirou,3 
Robert F. Spiera,4 Mary K. Crow,1,3 Jessica K. Gordon,4 Franck J. Barrat1*
Systemic sclerosis (SSc) is a multisystem life-threatening fibrosing disorder that lacks effective treatment. The link 
between the inflammation observed in organs such as the skin and profibrotic mechanisms is not well under-
stood. The plasmacytoid dendritic cell (pDC) is a key cell type mediating Toll-like receptor (TLR)–induced inflam-
mation in autoimmune disease patients, including lupus and skin diseases with interface dermatitis. However, the 
role of pDCs in fibrosis is less clear. We show that pDCs infiltrate the skin of SSc patients and are chronically acti-
vated, leading to secretion of interferon- (IFN-) and CXCL4, which are both hallmarks of the disease. We demon-
strate that the secretion of CXCL4 is under the control of phosphatidylinositol 3-kinase  and is due to the aberrant 
presence of TLR8 on pDCs of SSc patients, which is not seen in healthy donors or in lupus pDCs, and that CXCL4 
primarily acts by potentiating TLR8- but also TLR9-induced IFN production by pDCs. Depleting pDCs prevented 
disease in a mouse model of scleroderma and could revert fibrosis in mice with established disease. In contrast, 
the disease was exacerbated in mice transgenic for TLR8 with recruitment of pDCs to the fibrotic skin, whereas 
TLR7 only partially contributed to the inflammatory response, indicating that TLR8 is the key RNA- sensing TLR in-
volved in the establishment of fibrosis. We conclude that the pDC is an essential cell type involved in the pathogen-
esis of SSc and its removal using depleting antibodies or attenuating pDC function could be a novel approach to 
treat SSc patients.
INTRODUCTION
Systemic sclerosis (SSc) is a multisystem, fibrosing disorder in which 
vasculopathy, autoimmunity, and inflammation lead to diverse life- 
altering and life-threatening clinical manifestations (1). SSc has the 
highest degree of morbidity and mortality of the rheumatic diseases 
with a 10-year mortality rate of 23 to 45% (2, 3). The female predom-
inance is about 4:1, and the usual age of onset is 35 to 55 years. The 
pathophysiology of SSc is not completely understood, but substantial 
evidence shows interplay between immunologic derangement, endo-
thelial dysfunction, and profibrotic mechanisms. In particular, the 
contribution of B cells has been well studied, and abnormalities of 
B cell function have been demonstrated both in animal models of SSc 
and in SSc patients (4, 5). A clear understanding of SSc pathogenesis 
has been impeded by the heterogeneous nature of the disease—which 
is seen clinically, serologically, and at the level of gene expression in 
the skin and peripheral blood (6). The management of most of the com-
plications of SSc is not standardized, with important discrepancies be-
tween experts in drug choices, especially after first-line agents (7). The 
modified Rodnan skin score, which can reproducibly assess skin in-
volvement, correlates with prognosis and disease progression in other 
organ systems as well. Studying the skin in SSc patients is thus of great 
interest because the involvement of the skin often reflects similar patho-
 logical processes in the bowel and lungs.
The past decade has seen a rebirth of interest in innate immunity, 
catalyzed in large part by studies of the Toll-like receptors (TLRs), one 
of the largest and best-studied families of pattern recognition recep-
tors (8–10). Endogenous ligands released from damaged tissues or 
apoptotic cells have been identified for most human TLRs, and the 
sensing of self nucleic acids through TLRs can play an important 
part in sterile inflammation and autoimmunity (11, 12). To prevent their 
unwanted activation by self nucleic acids, the nucleic acid–sensing TLRs 
are contained in endosomes rather than on the cell surface, and their 
expression is tightly regulated. Indeed, the increased expression of either 
TLR7 or huTLR8 in transgenic mice is enough to induce autoimmunity 
even in the absence of any other genetic alterations (13–15). Further-
more, the biological consequence of TLR signaling is highly dependent 
on the pattern of expression of individual TLRs on hematopoietic cells. 
For example, although human TLR7 and TLR8 share similar recog-
nition of single-stranded RNA (ssRNA), we and others have shown 
that they have a distinct expression pattern in human blood cells (15–18), 
which leads to different quantitative and qualitative immune responses. 
In particular, TLR8 is absent in plasmacytoid dendritic cells (pDCs), 
which is reflected by the absence of interferon- (IFN-) induction 
when human peripheral blood mononuclear cells (PBMCs) are activated 
with a TLR8 agonist, in contrast to what is seen with TLR7 (15). In addi-
tion, understanding the function of TLR8 has proven difficult because 
the mouse TLR8, although a potentially functional receptor (19, 20), 
differs from its human ortholog due to the lack of five amino acids that 
are key for RNA recognition (21).
In at least two instances, the pDC is the key cell type mediating 
TLR-induced inflammation in autoimmune disease patients. In lupus, 
we and others have shown that pDCs produce large amounts of type I 
IFN due to TLR7 and TLR9 recognition of endogenous RNA and DNA 
in the form of immune complexes (22–24). We also showed that pDC 
activation prevents optimal response to corticosteroid treatment by 
lupus patients (25), and two recent studies identified pDCs as the key 
cell type promoting lupus in mouse models of the disease (26, 27). 
The importance of pDCs has also been observed in a series of related 
cutaneous autoimmune diseases such as dermatomyositis, lichen 
sclerosus, cutaneous graft-versus-host disease, or cutaneous lupus that 
share a common pathological inflammatory feature described as 
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“interface dermatitis” (28). In these patients, pDCs massively infiltrate 
the skin and produce IFN-, which plays a major role in the develop-
ment of cutaneous lesions. In this setting, using a skin injury model, 
we and others have demonstrated that pDCs are a dominant player in 
the autoimmune inflammatory damage (29, 30).
Recent reports have indicated that pDCs may also be associated 
with the pathogenesis of SSc. First, it was recently shown that pDCs 
traffic to the skin in a mouse model of the stiff skin syndrome (31). 
It was also shown that pDCs from SSc patients can secrete CXCL4 
and that serum levels of CXCL4 correlated with skin and pulmonary 
disease in these patients, although it was not shown whether pDCs are 
the only cells contributing to CXCL4 increased levels (32). CXCL4, 
also known as platelet factor 4, is released at high concentrations from 
activated platelets (33), and although not well defined, the function of 
CXCL4 seems to be associated with coagulation and inflammation.
Although it is well described that pDCs infiltrate the skin following 
injury or in certain diseases, little is known about what is controlling 
pDC trafficking and subsequent activation in the skin or whether pDCs 
Fig. 1. pDCs infiltrate the skin of SSc patients and spontaneously secrete IFN- and CXCL4. Skin biopsies from (A) control subjects or (B) systemic sclerosis (SSc) 
patients were immunostained for CD123 (red signal; original magnification, ×200; inset, ×400), and (C) quantification of the number of CD123+ counted in five high-power 
microscopic fields (based on five bioptic samples of patients with SSc and of five controls) is shown. (D) Representative dot plots of plasmacytoid dendritic cells (pDCs), 
B cells, conventional DCs (cDCs), and monocytes from peripheral blood mononuclear cells (PBMCs) from healthy donors (HDs) or SSc patients analyzed by flow cytometry. 
(E) Percentages of pDCs, monocytes, B cells, and cDCs within PBMC of either HDs (open circle, n = 10 to 15) or SSc patients (n = 14 to 33) defined as early diffuse (closed 
circle), late diffuse (closed square), or limited (closed triangle) were quantified by flow cytometry. ns, not significant. (F) Purified pDCs from HDs (n = 8) or SSc patients (n = 20) 
were cultured for 24 hours without stimuli. CXCL4 and interferon- (IFN-) were quantified by enzyme-linked immunosorbent assay (ELISA). Results were normalized to 
10,000 cells to account for the differences between donors in the number of cells put in culture. (G) The mean fluorescence intensity (MFI) of the costimulatory molecules 
CD83 and CD86 expressed on pDCs (n = 10 for HDs; n = 33 for SSc patients) was quantified by flow cytometry. Statistical significance was evaluated using a Mann-Whitney 
U test. *P < 0.05, **P < 0.01, ***P < 0.001.
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can play a role in promoting/sustaining inflammation-related fibrosis. 
The nature of pDC activation in SSc patients, the role of TLRs, and the 
impact of CXCL4 on pDCs response are also unknown.
RESULTS
pDCs infiltrate the skin of SSc patients and are chronically 
activated with spontaneous secretion of CXCL4 and IFN-
Activated pDCs have been observed to accumulate in the skin of SSc 
patients (32) in a similar way to what has been observed in skin lesions 
in diseases characterized by interface dermatitis (28). We observed the 
presence of pDCs in skin biopsies of SSc patients but not of healthy 
donor (HD) (Fig. 1, A to C), highlighting the role played by these cells 
in patients and confirming the importance of better understanding 
what controls their activation in the skin of patients. Similar to what 
has been shown in lupus patients (34, 35), we noted a significant (P < 
0.001) decrease in the number of pDCs circulating in the blood of SSc 
patients as compared to HDs (Fig. 1, D and E). This decrease is an indi-
cator of in vivo activation of pDCs and their migration into peripheral 
lymphoid tissues and to the skin (Fig. 1, A to C). No significant differ-
ence was observed in total B cells or conventional dendritic cells (cDCs), 
whereas monocytes were increased (Fig. 1, D and E). When cultured in 
the absence of additional stimuli, purified pDCs from the blood of pa-
tients spontaneously secreted IFN- but also CXCL4 (Fig. 1F), a 
chemokine recently identified as a biomarker for the disease (32). In 
some cases, the quantity of IFN was below the detection level of our 
assay. The kinetics of IFN- production by pDCs is rapid, which may 
explain the low levels of IFN, as the cell preparation likely contains a 
mix of cells recently activated along with cells activated more than 
24 hours. There was no difference in the secretion of any other 
chemokine analyzed, namely, CCL3, CCL4, and CCL5, between SSc 
and HD pDCs nor did we observe secretion of tumor necrosis factor 
(TNF), IFN-, or interleukin-12p40 (IL-12p40) from either SSc or HD 
pDCs. We have showed that pDCs, when activated, can up-regulate 
costimulatory molecules such as CD80, CD83, or CD86 and then ma-
ture into antigen-presenting cells (36, 37). We observed that pDCs from 
Fig. 2. TLR8 is aberrantly expressed on pDCs from SSc patients. (A) TLR8 expression levels [relative Ct (Rel Ct)] were quantified in purified pDCs [n = 18 HDs; n = 29 SSc pa-
tients; n = 6 systemic lupus erythematosus (SLE) patients], B cells (n = 14 HDs; n = 8 SSc patients), or monocytes (n = 17 HDs; n = 11 SSc patients) from PBMCs as indicated. (B to 
D) Gene expression level of TLR7, TLR9, and TLR10 was quantified in (B) purified pDCs (n = 17 to 18 HDs; n = 29 to 31 SSc patients; n = 6 SLE patients), (C) purified B cells (n = 12 
to 14 HDs; n = 6 to 8 SSc patients), or (D) purified monocytes (n = 16 to 18 HDs; n = 11 SSc patients) by quantitative polymerase chain reaction (qPCR). All results are represented 
as means ± SEM. Statistical significance was evaluated using a Mann-Whitney U test, and only comparisons that are significant are shown. *P < 0.05, **P < 0.01, ***P < 0.001.
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SSc patients did not express these costimulatory molecules (Fig. 1G), 
demonstrating that the chronic activation of pDCs in these patients 
likely involved the IFN pathway without the involvement of nuclear 
factor B (NF-B)–dependent signals, which are required for the in-
duction of these costimulation molecules (37).
pDCs from SSc patients display an aberrant expression 
profile of TLRs with the presence of TLR8
The sensing of nucleic acids by TLRs leads to substantial production 
of IFN- by pDCs, suggesting that the chronic activation of pDCs in 
SSc patients may involve TLRs. We thus quantified the mRNA expres-
sion levels of the nucleic acid–sensing TLR7, TLR8, and TLR9, as well as 
TLR10 on purified pDCs from SSc patients, systemic lupus erythematosus 
(SLE) patients or HDs. Similar to HDs, pDCs from SSc patients expressed 
both BDCA2 and BDCA4 (fig. S1), and we confirmed that monocytes 
from SSc patients did not have an aberrant expression of BDCA4 
(fig. S2). The expression levels of TLR7, TLR9, and TLR10 were similar in 
PBMCs prepared from SSc patients or HDs and were equally reduced in 
pDC-depleted PBMCs, which is expected because these three TLRs are 
normally expressed on pDCs (fig. S3A). However, we observed that 
TLR8 expression was increased in PBMCs of SSc patients and surpris-
ingly that the levels of expression of TLR8 in patients were normalized 
to those of HDs when pDCs were depleted from PBMCs (fig. S3A). In 
these experiments, monocytes were not affected by the depletion protocol 
(fig. S4), which is consistent with their lack of BDCA4 expression (fig. S2).
Furthermore, although pDCs isolated from HDs did not express 
TLR8 as has repeatedly been shown (15–18), we observed aberrant 
expression of TLR8 in pDCs isolated from the blood of SSc patients 
(Fig. 2A). The presence of TLR8 on pDCs was seen in 25 of the 29 pa-
tients tested, including patients with early or late diffuse SSc but also in 
patients with limited SSc. We also observed that TLR8 was not expressed 
on pDCs isolated from lupus patients (Fig. 2A), another disease where 
pDCs have been involved. Although our gating strategy excluded cell 
types known to express TLR8 (see Materials and Methods), we confirmed 
that we could not detect markers for non-pDC cells (in particular neutro-
phils that express abundant TLR8), which excludes a contribution of con-
taminating cells to our results. Similar findings were obtained using pDCs 
from HDs or SLE patients. These data thus suggest that the pDCs from 
SSc patients do express TLR8, which appears to be a feature of SSc. We 
tested various inflammatory cocktails of cytokines, including IFN- and 
IFN-, IL-12, IL-6, IL-10, TNF, or TGF- (transforming growth factor–), 
to determine what is regulating TLR8 expression on pDCs of SSc patients, 
but none of these molecules could induce TLR8 on pDCs of HDs (fig. S3B). 
In particular, CXCL4 or IFN-γ–induced protein 10 (IP-10) (two CXCR3B 
Fig. 3. TLR8 signaling induces CXCL4 and IFN- secretion by SSc PDCs. (A) Gene expression levels of CXCL4 were quantified in total PBMC or pDC–depleted (dep) 
PBMC prepared from either HDs (n = 6) or SSc patients (n = 23) by qPCR. Statistical significance was evaluated using the unpaired Mann-Whitney test between HD and 
SSc PBMC and with a paired t test between PBMC and pDC-depleted PBMC from SSc patients. (B) Purified pDCs from HDs (n = 4 to 10) were cultured either with media 
(Med) alone as a control or in the presence of a TLR7 agonist [heat-inactivated VR95 influenza virus at a multiplicity of infection (MOI) of 2], a TLR8 agonist (ORN-8L at 200 g/ml), 
or a TLR9 agonist (CpG-C274 at 0.5 M), and 24 hours later, CXCL4 in the supernatants was measured by ELISA. Results were normalized to the value of media alone and 
represented as means ± SEM. (C and D) pDCs purified from SSc patients (n = 15 and 12, respectively) were cultured for 24 hours either in media alone or with either (C) 
ORN-8L or (D) CpG-C274, and CXCL4 production was analyzed by ELISA. Results were normalized to control and represented as means ± SEM. (E) HD (n = 10) and SSc pDCs 
(n = 20) were stimulated with ORN-8L for 24 hours, and supernatants were collected for measurement of IFN-, IP-10, IL-6, and TNF by multiplex bead assay. Results were 
normalized to 10,000 cells. (F) Purified pDCs from SSc patients (n = 12) were cultured either with media alone or in the presence of a TLR9 agonist for 24 hours, and super-
natants were collected for measurement of IFN-, IP-10, IL-6, and TNF by multiplex bead assay. Results were normalized to 10,000 cells. All results are represented as means ± 
SEM. For (B) to (E), statistical significance was evaluated using a Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001.
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agonists) had no impact on TLR8 nor TLR7 and TLR9 expression levels in 
pDCs (fig. S3C). This dysregulation of TLR8 expression was not observed 
in other cell subsets including monocytes, which naturally expressed 
TLR8 with similar expression between HDs and SSc patients (Fig. 2A). 
Similar to pDCs, purified B cells from HDs do not express TLR8, and we 
observed that TLR8 was not present in B cells from SSc patients (Fig. 2A), 
suggesting that the dysregulation of TLR8 is a distinct feature of pDCs of 
SSc patients. TLR7 and TLR10 expression was similar in SSc and HD 
pDCs, whereas TLR9 expression was slightly decreased in SSc pDCs, as is 
often the case when pDCs are activated (Fig. 2B). Of note, expression of 
TLR7 and TLR9 was significantly greater (P < 0.01 and P < 0.001, respec-
tively) in pDCs of SLE patients as compared to SSc patients (Fig. 2B). No 
difference was observed in B cells or monocytes for TLR7, TLR9, or 
TLR10 (Fig. 2, C and D). These data suggest that in addition to being 
chronically activated, pDCs of SSc patients have an abnormal profile 
of TLRs characterized by the expression of TLR8.
TLR8 signaling in pDCs of SSc patients induces CXCL4, 
whereas TLR7 and TLR9 do not
The chemokine CXCL4 can be secreted by many cells within the 
PBMCs including pDCs (32) and was more abundant in PBMCs from 
SSc patients as compared to HDs [Fig. 3A and (32)]. However, 
when pDCs were depleted from PBMCs, the increased secretion of 
CXCL4 observed in SSc PBMCs was normalized to HD PBMC levels 
(Fig. 3A), demonstrating that the excess of CXCL4 observed in PBMCs 
of SSc patients is solely due to the activation of pDCs and not to the 
contribution of other cell types.
Culturing pDCs purified from HDs with agonists of either TLR7 
or TLR9 did not lead to CXCL4 production (Fig. 3B). In contrast, we 
observed that TLR8 but not TLR9 signaling could further induce CXCL4 
secretion by pDCs from SSc patients (Fig. 3, C and D). The triggering 
of TLR8 in pDCs of SSc patients also induced the production of IFN-, 
IP-10, IL-6, and TNF, whereas it had no effect on HD pDCs (Fig. 3E). 
Although TLR9 signaling did not induce CXCL4, the response by pDCs 
from SSc patients was otherwise normal with the induction of IFN-, 
IP-10, IL-6, and TNF (Fig. 3F). Together, these data demonstrate that 
the aberrant expression of TLR8 on the pDCs of these patients can 
change the nature of the response of those cells to nucleic acids and 
can induce the secretion of CXCL4. This is a unique situation where 
the atypical expression of a TLR on a cell type can affect the nature 
of its response, with a clear association with a disease.
CXCL4 exacerbates the TLR-mediated IFN- response in SSc 
pDCs, and its production is under the control of the  
P13K pathway
Very little is known on how CXCL4 can affect immune function and 
whether this chemokine has any effect on the direct induction of fibro-
sis in patients. In contrast, the contribution of type I IFN and pDCs has 
been well described in many autoimmune diseases and although its 
effect on fibrosis is more controversial, the presence of an IFN-related 
gene signature has been described in SSc patients (38–40). This raises 
the question as to whether the impact of CXCL4 in SSc patients is solely 
to potentiate the pathogenic IFN response or to promote an inflam-
matory response independently of the IFN pathway. When purified pDCs 
from HDs or SSc patients were cultured with CXCL4 alone, there was no 
effect on IFN production. However, we observed that adding CXCL4 
significantly increased (P < 0.001) the production of IFN- and of IP-10 
in response to TLR8 by purified pDCs from SSc patients (Fig. 4A), 
whereas it had no effect on IL-6 or TNF production (Fig. 4B). This 
observation indicates that in addition to its potential direct effect on 
other immune functions, CXCL4 has a critical role in potentiating the 
TLR-induced IFN production in SSc patients.
Although purified pDCs from SSc patients can spontaneously se-
crete IFN- and CXCL4 (Fig. 1F), we did not observe an increase of 
costimulatory molecules on these cells (Fig. 1G), suggesting that the 
chronic activation of pDCs in these patients likely involves the tran-
scription factor IRF7 (IFN regulatory factor 7) (41). We have previously 
shown that IRF7 translocation to the nucleus of pDCs and subsequent 
production of IFN- are under the strict control of phosphatidylinositol 
3-kinase  (PI3K) (41) and thus decided to test the involvement of PI3K 
in controlling pDC activation in SSc patients. When cultured in the pres-
ence of the specific inhibitor of PI3K CAL-101, the secretion of both 
CXCL4 and IFN- was inhibited and normalized to that of HD pDCs 
Fig. 4. CXCL4 potentiates TLR8- 
mediated activation of SSc pDCs. 
(A and B) Purified pDCs from SSc 
patients (n = 8) were cultured in 
media alone (control), with ORN-8L 
(200 g/ml), or with ORN-8L and 
CXCL4 (10 g/ml) for 24 hours, and 
(A) IFN- and IP-10 or (B) IL-6 and 
TNF were quantified in the superna-
tants by ELISA. Values were normal-
ized to ORN-8L alone and represented 
as means ± SEM. (C to E) Purified pDCs from HDs were cultured alone, and purified 
pDCs from SSc patients were cultured for 24 hours either alone or in the presence 
of the PI3K inhibitor CAL-101 (10 M); (C) CXCL4, (D) IFN-, or (E) IL-6 levels were 
quantified by ELISA. Results are normalized to 10,000 cells. All results are represented 
as means ± SEM, and statistical significance was evaluated using a Mann-Whitney U test. 
*P < 0.05, **P < 0.01, ***P < 0.001.
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(Fig. 4, C and D). CAL-101 was used at a concentration that can effec-
tively block TLR9-induced IFN production by pDCs from HDs without 
affecting IL-6 production or cell viability (fig. S5, A and B). Blocking 
PI3K had no effect on the secretion of IL-6 by pDCs of SSc patients 
(Fig. 4E), which indicates that inhibiting PI3K could block the chronic 
activation of pDCs in SSc patients without globally affecting the ability 
of these cells to be activated in response to pathogens.
CXCL4 potentiates TLR9-induced IFN- but has minimal 
effect on TLR7-mediated activation of pDCs purified  
from either HDs or SSc patients
We also measured the effect of CXCL4 on TLR7- and TLR9-induced 
response by human pDCs from both HDs and SSc patients. These two 
TLRs can induce high levels of IFN- by human pDCs, and recent find-
ings suggested that TLR9-induced IFN- production was reduced 
by blocking CXCL4 (32). To evaluate the impact of CXCL4 on TLR- 
induced pDCs response, we used agonists of TLR7 and TLR9 at sub-
optimal doses and used both a CpG-C and a CpG-B oligodeoxynucleotide 
(ODN). We observed that CXCL4 drastically affected the TLR9 response 
irrespective of the CpG used (Fig. 5, A and B) with little to no effect 
on the TLR7 response (Fig. 5C). This effect was similar both in HDs 
(Fig. 5, A to C) and SSc patients (Fig. 5, D and E), which is consistent with 
the fact that CXCR3B is expressed at similar level in purified pDCs of 
HDs and SSc patients (fig. S6) and CXCL4 itself did not induce IFN-. 
These data thus suggest that the effect of CXCL4 is not restricted to 
TLR8 in patients and can affect TLR9 as well.
pDCs are required for the establishment and maintenance of 
skin fibrosis in a mouse model of scleroderma
The display of an IFN signature in SSc patients (38–40), the presence 
of pDCs in the skin of localized scleroderma (morphea) and of SSc 
patients (Fig. 1A) (32, 42), and our new data showing that pDCs are 
chronically activated in SSc patients suggest that pDCs may participate 
in the pathogenesis of the disease. However, whether pDCs directly 
contributes to the fibrosis in the skin is unclear.
To address this question, skin fibrosis was induced in C57/BL6 mice 
by injection of bleomycin (BLM), a cancer drug that has long been 
known to cause fibrosis. In mice, BLM treatment constitutes a well- 
characterized mouse model for SSc and can induce skin fibrosis with a 
prevalence of almost 100% (43, 44), leading to increased skin thickness 
and loss of the subcutaneous fat in favor of sclerotic tissue (45). The fi-
brotic outcome of BLM treatment encompasses collagen deposition in the 
skin and the induction of –smooth muscle actin (-SMA)–positive 
stromal cells. We first confirmed that pDCs infiltrate the skin in this 
model after 4 weeks of BLM injection by measuring the presence of 
Siglec-H+ cells in the skin (Fig. 6, A to D). The immunohistochemistry 
staining was confirmed using in situ RNA hybridization for the siglech 
transcript in the skin of phosphate-buffered saline (PBS)– or BLM-treated 
mice (fig. S7, A and B). To evaluate the direct contribution of pDCs in 
skin fibrosis, these cells were depleted using CLEC4C-DTR (C-type lec-
tin domain family 4, member C2-diphtheria toxin receptor) transgenic 
mice by injection of diphtheria toxin (DT) starting 24 hours before the 
first BLM injection and continuing through the entire experiment. As 
previously described (27), DT injection in CLEC4C-DTR mice is very 
efficient in specifically deleting pDCs (fig. S7, C and D) and does not 
affect other cell types in mice (fig. S7E), and we observed a significant 
reduction (P < 0.01) of pDC infiltration in the skin of the mice (Fig. 6, A 
to D). The loss of pDCs led to a significant reduction (P < 0.001) in the 
skin thickness of BLM-injected mice with an almost preserved subcuta-
neous fat (Fig. 6, E and F) and a normal content of collagen in the skin 
(Fig. 6G). Dermal myofibroblasts have the capacity to synthesize and 
deposit extracellular matrix components (46) and can be identified by 
expression of -SMA. The depletion of pDCs resulted in a signifi-
cantly decreased number of these cells (P < 0.001) as compared to pDC- 
sufficient mice (Fig. 6, H and I, and fig. S7F). The expression of TGF-, 
a well-known marker of fibrosis for its impact on the synthesis and depo-
sition of extracellular matrix by fibroblasts (47), was also reduced in 
pDC-depleted mice (Fig. 6J).
We have shown that pDCs can induce a strong IFN response in the 
skin following injury (29), and the same was observed in this fibrosis model, 
with the presence of multiple IFN-regulated genes in BLM-treated 
animals, genes that were not expressed in pDC-depleted BLM-treated 
animals (Fig. 6K). We also observed a blockade of proinflammatory 
cytokines/chemokines such as TNF and monocyte chemoattractant 
protein–1 (MCP-1) (Fig. 6L) that have been associated with fibrosis 
(48, 49) in pDC-depleted mice, which was accompanied by a reduction 
in the overall immune cell infiltration in the skin. These data dem-
onstrate that the pDC is a critical cell type directly involved in skin 
Fig. 5. CXCL4 potentiates 
TLR9-mediated activation 
but has minimal effect 
on TLR7-mediated activa-
tion of pDCs purified from 
SSc or HDs. Purified pDCs 
from HDs (A to C) or SSc 
patients (D and E) were cul-
tured in media alone (con-
trol), either (A and D) with a 
CpG-C TLR9 agonist (0.1 M) 
or with CpG-C and CXCL4 
(10 g/ml), or (B) with a CpG-B TLR9 agonist (0.25 M) or with CpG-B and 
CXCL4, and (C and E) with a TLR7 agonist [heat-inactivated VR95 influenza 
virus at a MOI of 0.5 (FLU)] or with FLU and CXCL4 for 24 hours (n = 6 to 18 as 
indicated). IFN- was quantified in the supernatants by ELISA. Values were 
normalized to 10,000 cells. All results are represented as means ± SEM, and 
statistical significance was evaluated using a Mann-Whitney U test. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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fibrosis because its depletion affects not only the inflammatory re-
sponse that is induced by BLM but also the actual fibrotic outcome.
The role of pDCs in the maintenance of the disease was evaluated 
by depleting pDCs after 3 weeks of BLM treatment followed by the 
continuation of the BLM injections for an extra 2 weeks. After 3 weeks 
of BLM treatment, we observed an increase of the skin thickness in the 
mice and increased infiltration of pDCs, and this was even more 
apparent after 5 weeks (Fig. 7, A and B). When pDCs were depleted 
at 3 weeks in mice that had already established disease, at 5 weeks, 
we observed a reduction of the skin thickness as compared to pDC- 
competent mice. Furthermore, mice that received BLM for 5 weeks 
with pDCs depleted at 3 weeks had reduced disease even compared 
to the mice treated with BLM for just 3 weeks (Fig. 7A). This suggests 
that pDCs are critical for the maintenance of fibrosis in the skin and 
Fig. 6. pDCs infiltrate the skin of BLM-treated mice, and their depletion attenuates skin fibrosis. pDC depletion was achieved as described in Materials and Methods. 
(A to C) Representative images of Siglec-H+ cells (red signal; original magnification, ×400) and (D) average (value based on five skin sections with n = 6 to 13 mice per group) 
in wild-type (WT) mice injected with (A) PBS and (B) with BLM and of (C) CLEC4C-DTR mice injected with DT and BLM. (E) Representative images of Masson’s trichrome–
stained skin sections at a ×10 magnification, arrow indicates the area used to quantify skin thickness, and (F) average of skin thickness of WT mice receiving PBS [left panel in 
(E); open circle in (F)], WT mice injected with DT and treated with BLM [middle panel in (E); closed circle in (F)], and CLEC4C-DTR mice injected with DT and BLM [right panel in 
(E); closed square in (F)] is shown. (G) Collagen content in the skin expressed as a ratio of collagen per total protein (tot prot.) is shown. (H and I) Representative images of 
–smooth muscle actin (-SMA) immunohistochemistry of the dermis at a ×40 magnification and averages of the number of -SMA–positive cells per surface area in dermis 
are shown. (J to L) Relative gene expression of the indicated genes using the NanoString technology. All values represent means ± SEM; n = 6 to 14 mice for each group. 
Data are cumulative of three independent experiments, and statistical significance was evaluated using a Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001.
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that their depletion leads to reversion of disease. Using in situ RNA 
hybridization for the cxcl4 transcript, we also show that the presence 
of pDCs in the skin correlated with the presence of CXCL4 (Fig. 7, C 
and D), which links both pDCs and CXCL4 to the promotion of skin 
fibrosis, although it is unclear whether CXCL4 is produced by the 
pDCs themselves, as it is in the human situation, or whether CXCL4 is 
produced by other cells that are recruited to the skin in a pDC- dependent 
manner because of the presence of multiple chemokines.
TLR8 exacerbates disease in the BLM-induced fibrosis model
We show herein that the aberrant expression of TLR8 in SSc pDCs 
leads to the production of both CXCL4 and IFN-, suggesting that this 
receptor has a key role in the disease. To better understand whether 
TLR8 can promote fibrosis in a relevant in vivo model, skin fibrosis 
was induced in mice that carry the human TLR8 gene that we have 
recently described (15). These mice, called huTLR8Tg or Tg8, have a 
single copy of the huTLR8 gene under the control of huTLR8 ge-
nomic regulatory regions, and TLR8 cellular distribution is similar to 
the human situation (15). In addition, we have evaluated the respec-
tive contribution of TLR7 and TLR8 to disease because both receptors 
recognize RNA and seem to regulate each other’s response (15, 19). 
We used genetically modified mice and performed BLM experiments 
using huTLR8Tg (have both functional TLR8 and TLR7), huTLR8Tg × 
TLR7ko (have functional TLR8 but no 
TLR7), TLR7ko (deficient for both TLR7 
and TLR8), and C57/BL6 mice, which are 
de facto TLR8- deficient but have TLR7. 
Upon BLM treatment, we observed ag-
gravated fibrosis and an increase of skin 
thickness in huTLR8Tg mice over wild-
type (WT) mice (Fig. 8, A and B). In ad-
dition, the infiltration of pDCs present in 
BLM-treated B6 mice was significantly 
increased in the TLR8Tg mice (Fig. 8, C 
and D) and did not require the presence 
of TLR7. The distribution of pDCs in the 
skin seemed altered in Tg8 mice with cells 
present in all the skin layers. Mice defi-
cient for TLR7 were not protected from 
BLM-induced fibrosis (Fig. 8, A and B), and 
huTLR8Tg × TLR7ko mice also showed 
exacerbated response to BLM as com-
pared to WT or TLR7ko mice (Fig. 8, A 
and B). Furthermore, we did not see sig-
nificant differences (P < 0.01) in disease 
between the huTLR8Tg and huTLR8Tg × 
TLR7ko mice, pointing to a dominant role 
of TLR8 in this disease (Fig. 8, A and B). 
However, some of the inflammation ob-
served in the skin could be partially at-
tributed to TLR7.
First, we observed that the infiltration of 
pDCs was reduced in TLR7ko mice (Fig. 8, 
C and D). Second, the inflammatory re-
sponse observed in the skin was depen-
dent on both TLR7 and TLR8 with key 
differences between the genes of interest 
(Fig. 8, E and F). The expression of genes 
such as CXCL9 (MIG), CXCL10 (IP-10), 
RANTES, or TNF seemed to be regulated by TLR8 signaling because 
their expression was increased in TLR8Tg mice irrespective of the 
presence of TLR7 (Fig. 8E). Other genes, mostly regulated by IFN-, 
were reduced in TLR7ko mice (with sometimes a contribution of 
TLR8) (Fig. 8, E and F), which may be explained by the reduced skin 
infiltration of pDCs observed in TLR7ko mice (Fig. 8, C and D). To 
better understand how the BLM model relates to the human situation 
with respect to TLR8 activation of pDCs, we quantified the expression 
levels of TLR8 in purified splenic macrophages, which we have shown 
to express huTLR8 (Fig. 8G) (15) or in splenic pDCs (Fig. 8H) in mice 
treated for 4 weeks either with PBS or BLM. We observed that in mice 
injected with PBS, pDCs do not express TLR8 but that this receptor is 
up-regulated in pDCs following the induction of fibrosis with BLM 
(Fig. 8H). Together, these data indicate that TLR8 is the key RNA- 
sensing TLR involved in the establishment of fibrosis and can pro-
mote not only an increase in the inflammatory response but also skin 
fibrosis.
DISCUSSION
In the past decade, substantial evidence has pointed to the involvement 
of self–nucleic acid recognition in inflammatory and autoimmune dis-
eases. This is particularly clear for TLR7 and TLR9, which can induce 
Fig. 7. pDCs are critical for the maintenance of skin fibrosis and for the presence of CXCL4 in the skin. Fibrosis 
was induced by injection of BLM in WT mice for either 3 or 5 weeks (wks) or in CLEC4C-DTR mice for 5 weeks as de-
scribed in Materials and Methods. At 3 weeks of BLM treatment, pDC depletion was achieved in CLEC4C-DTR mice by 
DT injection (in red) while fibrosis induction was sustained for 2 more weeks. (A) Average of skin thickness and (B) of 
the number of Siglec-H+ cells in the skin. (C) Representative images of the cxcl4 transcript by RNA in situ hybridization 
(brown signal; original magnification, ×400; inset, ×630) and (D) average of the number of CXCL4+ cells. Experiment 
was performed twice (n = 4 to 10 per group). All results are represented as means ± SEM, and statistical significance 
was evaluated using a Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001.
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type I IFN from pDCs but also promote the activation of self-reactive 
B cells. Their involvement in diseases such as lupus or skin diseases has 
been demonstrated in multiple preclinical studies, both in human and 
mouse models (11, 12). The role of TLR8 is less clear, although we have 
shown that mice overexpressing TLR8 develop a multiorgan inflam-
matory response leading to autoimmune pancreatitis and spontaneous 
arthritis (15). The contribution of TLRs to autoimmunity has been 
highlighted in multiple disease models and has been supported by two 
Fig. 8. TLR8 exacerbates disease in the BLM-induced fibrosis model. 
(A) Representative images of Masson’s trichrome–stained skin sections at 
a magnification of ×10 of WT mice injected with PBS or WT mice, Tg8 mice, 
TLR7KO mice, and Tg8 × TLR7KO (Tg8 × 7KO) mice injected with BLM. 
(B) Average of skin thickness (n = 11 to 18 per group). (C) Representative 
images of Siglec-H+ cells in the skin of WT mice injected with PBS or with 
BLM and of Tg8 mice, TLR7KO mice, and Tg8 × TLR7KO mice injected with 
BLM. (D) Histograms represent number of Siglec-H+ cells and are cumulative 
of at least 10 mice from three independent experiments. (E and F) Relative 
expression of indicated genes regulated by TLR8 and/or TLR7 using the 
NanoString technology. (G and H) Gene expression levels of huTLR8 by 
qPCR for (G) macrophages (F4/80+, CD11b+) or (H) pDCs (F4/80−, CD11b− and B220+, Siglec-H+, BST2+) purified from WT or Tg8 mice (n = 3 to 4) that received PBS or 4 weeks 
of BLM as indicated (see Materials and Methods). All results are represented as means ± SEM from three to six independent experiments for each group, and statistical 
significance was evaluated using a Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001.
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critical sets of evidence. First, it has been shown that TLRs, and in par-
ticular the nucleic acid–sensing TLRs, can recognize self-ligands, lead-
ing to an unwanted inflammatory response. The clearest example is the 
role played by TLR9 and TLR7 in lupus following the accumulation of 
self-DNA/RNA via immune complexes (22–24, 50). Another example 
is the importance of self–antimicrobial peptides in promoting auto-
immunity (51). Second, it has been shown that the overexpression of 
TLRs alone is sufficient to induce autoimmunity in otherwise WT ani-
mals, as shown for TLR7 or TLR8 (13–15).
One of the main unresolved questions is to define which cell types 
are mediating the inflammatory response following nucleic acid sensing, a 
challenge that is augmented by the significant species differences be-
tween rodents and humans in TLR expression patterns. This is partic-
ularly true for the RNA-sensing TLR7 and TLR8 because of the lack of 
an appropriate animal model to study their respective functions in 
vivo. Our understanding of the contribution of TLR8 to inflammation 
has been mostly based on findings using mouse TLR7, which, similar 
to human TLR8, can recognize ssRNA in the endosome but has dras-
tically different cellular distribution and ligand specificity (17).
We used genetically modified mice to address these challenges and 
to demonstrate the relevance of our findings to SSc patients. pDCs 
were depleted in CLEC4C-DTR mice using similar treatment to that 
recently described in a mouse model of lupus (27), which allowed us to 
test the direct impact of pDCs in both the establishment and mainte-
nance of skin fibrosis in vivo. We also used huTLR8CL8 transgenic 
mice to characterize the role of TLR8 in vivo because these mice have 
a single copy of the TLR8 gene and no spontaneous inflammatory 
phenotype or abnormalities but respond to agonists of human TLR8 
in vivo (15). The role of both RNA-sensing TLRs was further tested by 
using mice deficient for TLR7, TLR8, neither, or both. Using these 
mice and samples from well-characterized SSc patients, we made the 
following observations. We observed that pDCs infiltrate the skin of 
SSc patients, as has been observed in other skin diseases (28), and we 
noted that the number of circulating pDCs is reduced in the blood of 
SSc patients, which indicates that the cells are activated, as has been 
shown in lupus and other skin diseases. This was not the case for total 
B cells, although it is possible that subsets of B cells or plasma cells may 
be affected in these patients and a number of clinical strategies are 
focusing on these cells. We show that pDCs purified from patients 
spontaneously secrete IFN- and CXCL4 but do not bear expression 
of costimulatory molecules, suggesting that the cells are activated but 
have not matured into fully differentiated DCs. At a mechanistic level, 
we demonstrate that this chronic activation of pDCs and subsequent 
production of CXCL4 and type I IFNs are due to the expression of 
TLR8 and its signaling on the pDCs of patients but not of HDs or of 
patients with SLE. When pDCs from HDs were cultured with agonists 
of TLR7 or TLR9, with IFN-, CXCL4, or other inflammatory cyto-
kines, none of these culture conditions affected TLR8 expression, and 
it is thus unclear what is controlling TLR8 expression in the pDCs of 
these patients. We also show that CXCL4 potentiates the TLR8- 
induced production of IFN by pDCs of SSc patients and that the pro-
duction of CXCL4 and IFN is under the strict control of PI3K. The 
effect of CXCL4 was also very pronounced on TLR9 signaling but did 
not affect TLR7, both in HDs and SSc patients. Our results are consis-
tent with the experiments described by van Bon et al. (32) where 
CXCL4 inhibition seemed to affect CpG-induced IFN response, al-
though levels of the IFN in response for TLR9 in that study was mod-
est (few hundreds pg/ml) as compared to what has been repeatedly 
described for CpG- activated pDCs. It is well established in other in-
dications such as lupus that TLR7 and TLR9 exert very distinct roles 
in the pathogenesis of disease. Lupus-prone mice deficient for TLR9 
have exacerbated disease, even though these mice have reduced amount 
of antinucleosome autoantibodies, whereas sim ilar mice deficient for 
TLR7 display milder autoimmunity. The mechanism underlying this 
difference is still unclear, and our observation that CXCL4 drastically 
affects TLR9-induced IFN-, whereas it has no effect on TLR7, may 
provide a first line of evidence that the signaling of these two recep-
tors can be differentially regulated by the inflammatory situation and 
highlights a potential role for TLR9 in SSc.
Our conclusions from patient samples were supported by our in vivo 
findings. We demonstrate that when pDCs are depleted (using CLEC4C-
DTR mice), mice are protected from disease using a scleroderma mouse 
model and that removing pDCs in already established disease led to re-
duced fibrosis, stressing the critical role played by pDCs in the disease. 
In addition to observing a reduction in the IFN response in the skin, the 
depletion of pDCs also led to a significant amelioration of skin fibrosis 
as measured histologically or through the presence of profibrotic genes 
highlighting the importance of pDCs in promoting fibrosis. Using 
TLR8TgCL8 mice and when compared to WT littermate controls, we 
observed an exacerbation of disease in the BLM mouse model of sclero-
derma, confirming in the mouse the key role played by TLR8. We also 
describe that TLR7 participates in the infiltration of pDCs in the skin of 
the sick mice and the subsequent IFN response but that TLR8 emerges 
as the dominant receptor driving fibrosis. We thus propose a model 
where the aberrant expression of TLR8 on pDCs from SSc patients in-
duces the secretion of CXCL4, which then can favor TLR responses, ul-
timately promoting autoimmunity and fibrosis leading to disease. It is 
worth noting though that the experiments where pDCs were depleted 
have been conducted in mice that do not express TLR8, suggesting that 
although TLR8 seems to be a key player in the pathogenesis of SSc, other 
TLR8-independent pathways are also involved in the disease. SSc is a 
complex and heterogeneous disease, and this suggests the existence of 
Table 1. Clinical and demographic characteristics of the SSc patients. 
Age—years, mean (SD) 51.32 (12.82)
Sex—n, % female 61, 77.2%
Race—n, %
55, 69.6% Caucasian
18, 22.8% African American
5, 6.3% Asian
Disease duration—years,  
mean (SD) 5.6 (4.9)
Scleroderma subtype 
n, % diffuse 62, 78.5%
n, % limited 13, 16.5%
MRSS—mean (SD) 16.4 (11)
Autoantibody  
n, % Scl70 28, 35.4% Scl70
n, % RNA polymerase 3 21, 26.6% POL3
n, % centromere 11, 13.9% CENB
n, % RNP 4, 5.06% RNP
Interstitial lung disease  
present—n, % 43, 54.4%
Pulmonary hypertension 
present—n, % 8, 10.1%
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multiple mechanisms involved in the pathogenesis of the disease. Fur-
thermore, platelets are the main source for CXCL4, which is an impor-
tant chemoattractant for neutrophils, monocytes, and fibroblasts. Our 
data argue for a role for platelets, via the production of CXCL4 (33), in 
potentiating TLR responses at the site of inflammation or in response to 
tissue injury both in normal and pathological situations.
We understand that there are inherent limitations in conducting such 
translational studies using patient’s samples. Most of our findings were 
gathered from blood samples, which only give a partial view of the in-
flammatory situation in tissues. Studies in vivo using mouse models did 
complement our findings in SSc patients, but there are limitations associ-
ated with the relevance of disease models in mice and in particular of the 
well documented differences in TLR biology between mice and humans.
There is no effective treatment for SSc, and there is a clear need to 
better understand the key factors that promote disease pathogenesis to 
develop new therapeutic strategies. The involvement of the skin is a key 
component of the disease in scleroderma, and symptoms can be affected 
by environmental exposure. Our findings that pDCs are a key player in 
promoting the disease and the definition of the role played by TLR8 and 
PI3K could open new ways to treat these patients. Our findings could 
not readily explain the female predominance observed in SSc because sim-
ilar overexpression of TLR8 was seen in male and female patients. It is 
worth noting however that TLR8 is expressed on the X chromosome, but it 
is unclear whether this predominance can be associated with TLR8 re-
sponse. pDCs are the main type I IFN producers in human blood and 
participate in antiviral immunity, but these cells have been associated with 
autoimmunity in various contexts, in particular in a number of cutane-
ous autoimmune diseases. Although it is well described that pDCs in-
filtrate the skin following injury, we know surprisingly little about what 
is controlling pDC trafficking and subsequent activation in the skin. 
Our data demonstrate that pDCs can also directly promote fibrosis 
since their deletion can prevent skin fibrosis even in already established 
disease. We also show that the pDC-driven inflammation in the skin 
seems to be associated with the actual skin fibrosis, and one hypothesis 
would be that the fibrotic response may start as part of a regulatory 
feedback to the inflammatory spur. Whether pDCs only take part in the 
inflammatory response or whether they have a direct effect on the pro-
duction of profibrotic mediators will be key to our understanding of 
how these cells contribute to disease. There are novel approaches to 
directly target pDCs using, for example, CD123- depleting antibodies 
or antibodies specific for BDCA2, which are currently in clinical de-
velopment (https://clinicaltrials.gov). In addition, many inhibitors of 
PI3K are available, including CAL-101, which was recently approved 
(under the name Zydelig) for three cancer indications, as well as other 
molecules that are being tested in autoimmune diseases. None of these 
molecules or approaches has been tested in patients with SSc, but our 
data now provide some rationale to explore those and other approaches 
such as direct inhibition of TLR8, type I IFN, or CXCL4-induced sig-
naling for the treatment of this devastating disease.
MATERIALS AND METHODS
Study design
The research objective of our study was to determine how pDCs, through 
TLR activation, might contribute to the pathogenesis of SSc. SSc pa-
tients between 21 and 79 years of age, SLE patients between 25 and 
54 years of age, and healthy donors between 27 and 60 years of age 
were included in the human study. Patients were treated with a variety 
of therapies. However, they were excluded from the B cell analysis if 
they received rituximab, and they were excluded from the TLR assays 
if they were treated with hydroxychloroquine. No blinding or ran-
domization was performed for the human studies. For in vivo studies, 
8- to 12-week-old female mice were used. Immunohistochemistry and 
immunostaining analyses were performed in a blinded manner. Pri-
mary data are located in table S3.
Mice and BLM model
C57BL/6 and CLEC4C-DTR transgenic mice (27) and TLR7ko mice 
were obtained from The Jackson Laboratory, and the TLR8Tg mice 
were generated as described (15). Skin fibrosis was induced using the 
BLM-induced model as originally described by Yamamoto (43, 44) and 
adapted for better consistency (45). BLM treatment can induce skin fi-
brosis in a small (about 1 cm) area at the site of injection with a prevalence 
of almost 100%. Mice (8- to 12-week-old female) received daily subcuta-
neous injections for 3 to 5 weeks in three adjacent spots on the shaved 
Table 2. Clinical and demographic characteristics of the SLE patients.  
Age—years, mean (SD) 40.67 (10.98)
Sex—n, % female 5, 83.33%
Race—n, %
2, 33.3% Caucasian
2, 33.3% African American
2, 33.3% Asian
Disease duration—years,  
mean (SD) 15 (3.29)
ACR criteria—n, %
 Malar rash 3, 50%
 Discoid rash 0, 0%
 Photosensitivity 3, 50%
 Oral ulcers 3, 50%
 Arthritis 5, 83%
 Serositis 3, 50%
 Renal disorder 2, 33%
 Neurologic disorder 0, 0%
 Hematologic disorder 6, 100%
 Immunologic disorder 5, 83%
 Positive ANA 6, 100%
Positive titer of 
anti-dsDNA—n, % total 3, 50%
 1+ positive 1
 2+ positive 1
 3+ positive 1
 4+ positive 0
History of positive  
anti-RBP—n, % total 4, 66.67%
 Anti-Ro 3
 Anti-La 1
 Anti-Sm 0
 Anti-RNP 3
SLEDAI—mean (SD) 4.5 (2.43)
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lower back either with 60 g (100 l) of filter-sterilized BLM or PBS. To 
deplete pDCs, CLEC4C-DTR mice were injected twice weekly by in-
traperitoneal injection with 400 ng of DT. Injections either started 1 day 
before and during the 4 weeks of experimental fibrosis or started at 
3 weeks after the start of the BLM injections and continued for the remain-
ing 2 weeks (BLM treatment was not interrupted). The depletion efficiency 
was confirmed by flow cytometry analysis of pDCs (B220+PDCA-1+) 
in the spleen (fig. S7, C and D). All animal procedures were performed 
in accordance with the regulations of the Institutional Animal Care and 
Use Committee of the Hospital for Special Surgery and Weill Cornell 
Medical College.
Details on the evaluation of skin fibrosis and gene expression anal-
ysis, in situ mRNA hybridization analysis, and immunohistochemical 
analysis and on how mouse macrophages and pDCs were isolated are 
provided in the Supplementary Materials.
Patients
Participants were recruited from the institutional review board– approved 
Hospital for Special Surgery Scleroderma or Systemic Lupus Erythema-
tosus Registries. Patients and healthy volunteers provided written in-
formed consent before enrollment. All SSc patients fulfilled the 2013 
ACR/EULAR classification criteria for SSc (52). Patients were catego-
rized as having limited cutaneous or diffuse cutaneous subtype of SSc 
according to LeRoy and Medsger Jr. (53). Disease duration was de-
fined as the time from the first SSc-related symptom apart from the 
Raynaud phenomenon and was classified as early if the disease dura-
tion was ≤2 years. The clinical and demographic characteristics of the 
SSc patients are described in Table 1 and table S1.
All SLE patients fulfilled the 1997 ACR criteria (54) and its comple-
mentary criteria, the 2012 Systemic Lupus International Collaborating 
Clinics criteria (55) for SLE patients. The clinical and demographic 
characteristics of the SLE patients are described in Table 2 and table S2.
Details on how cells were purified from the blood of HDs or patients, 
on the flow cytometry staining and analysis, on real-time quantitative 
polymerase chain reaction analysis, and on measurement of chemo-
kines and cytokines are provided in the Supplementary Materials.
Statistical analysis
Data were analyzed using a Mann-Whitney U test (t test using non-
parametric criteria for independent samples). Comparisons between 
PBMC and pDC-depleted PBMC were tested using a parametric paired 
t test. All analyses were performed using Prism software (GraphPad 
Software). Differences were considered significant at a P level less than 
0.05 with *P < 0.05, **P < 0.01, ***P < 0.001.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/10/423/eaam8458/DC1
Materials and Methods
Fig. S1. BDCA4-positive cells express BDCA2, and both are specific markers for pDC.
Fig. S2. Monocytes of SSc do not express BDCA4.
Fig. S3. Reduction of the expression levels of TLRs in pDC-depleted PBMC.
Fig. S4. Monocytes are not depleted in pDC-depleted PBMC.
Fig. S5. CAL-101 specifically inhibits IFN- but not IL-6 production by TLR9-activated pDCs.
Fig. S6. pDCs purified from HDs or SSc patients have similar expression of CXCR3B.
Fig. S7. Injection of DT leads to the specific depletion of pDCs in CLEC4C-DTR mice.
Table S1. Clinical and demographic characteristics of the 79 individual SSc patients as well as 
the overall description of the patient population are shown.
Table S2. Clinical and demographic characteristics of the six individual SLE patients as well as 
the overall description of the patient population are shown.
Table S3. Primary data.
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targeting these cells could help patients with this devastating disease.
Depletion of pDCs from mice with established fibrosis ameliorated disease symptoms, further suggesting that
secretion of CXCL4. These data were garnered from systemic sclerosis patient samples and mouse models. 
systemic sclerosis, largely through activation of TLR8, which is not normally expressed in these cells, and
multiple autoimmune disorders. Here, Ah Kioon and colleagues show that pDCs contribute to skin fibrosis in 
As potent producers of type I interferon, plasmacytoid dendritic cells (pDCs) have been implicated in
Plasmacytoid DCs foster fibrosis
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